These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32860470)

  • 1. A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.
    Law M; Grayling MJ; Mander AP
    Pharm Stat; 2021 Mar; 20(2):212-228. PubMed ID: 32860470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stochastically curtailed single-arm phase II trial design for binary outcomes.
    Law M; Grayling MJ; Mander AP
    J Biopharm Stat; 2022 Sep; 32(5):671-691. PubMed ID: 35077268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Group sequential designs for stepped-wedge cluster randomised trials.
    Grayling MJ; Wason JM; Mander AP
    Clin Trials; 2017 Oct; 14(5):507-517. PubMed ID: 28653550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A confidence function-based posterior probability design for phase II cancer trials.
    Shan M
    Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
    Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
    Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears.
    Parsons N; Stallard N; Parsons H; Wells P; Underwood M; Mason J; Metcalfe A
    Trials; 2019 Dec; 20(1):694. PubMed ID: 31815651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
    Bratton DJ; Phillips PP; Parmar MK
    BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
    Hague D; Townsend S; Masters L; Rauchenberger M; Van Looy N; Diaz-Montana C; Gannon M; James N; Maughan T; Parmar MKB; Brown L; Sydes MR;
    Trials; 2019 May; 20(1):294. PubMed ID: 31138292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.